All Stories

  1. BIRC5/Survivin is a novel ATG12–ATG5 conjugate interactor and an autophagy-induced DNA damage suppressor in human cancer and mouse embryonic fibroblast cells

    Article • Autophagy, October 2019, Taylor & Francis

    Dr Mohane Coumar, Professor Chun Hei Antonio Cheung

  2. Dysfunction of different cellular degradation pathways contributes to specific β-amyloid42–induced pathologies

    Article • The FASEB Journal, March 2018, Federation of American Societies For Experimental Biology (FASEB)

    Professor Chun Hei Antonio Cheung

  3. Delivery of a survivin promoter-driven antisense survivin-expressing plasmid DNA as a cancer therapeutic: a proof-of-concept study

    Article • OncoTargets and Therapy, May 2016, Dove Medical Press

    Professor Chun Hei Antonio Cheung

  4. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers

    Article • Drug Discovery Today, May 2015, Elsevier

    Professor Chun Hei Antonio Cheung

  5. O6-methylguanine DNA methyltransferase repairs platinum-DNA adducts following cisplatin treatment and predicts prognoses of nasopharyngeal carcinoma

    Article • International Journal of Cancer, March 2015, Wiley

    Professor Chun Hei Antonio Cheung

  6. Competitive inhibition of survivin using a cell-permeable recombinant protein induces cancer-specific apoptosis in colon cancer model

    Article • International Journal of Nanomedicine, February 2015, Taylor & Francis

    Dr krishnakumar subramanian, Professor Chun Hei Antonio Cheung

  7. Locked nucleic acid modified bi-specific aptamer-targeted nanoparticles carrying survivin antagonist towards effective colon cancer therapy

    Article • RSC Advances, January 2015, Royal Society of Chemistry

    Professor Chun Hei Antonio Cheung

  8. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells

    Article • British Journal of Pharmacology, December 2014, Wiley

    Professor Chun Hei Antonio Cheung

  9. Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 – 2013)

    Article • Expert Opinion on Therapeutic Patents, June 2014, Informa Healthcare

    Professor Chun Hei Antonio Cheung

  10. Autophagy induced by cathepsin S inhibition induces early ROS production, oxidative DNA damage, and cell death via xanthine oxidase

    Article • Free Radical Biology and Medicine, December 2013, Elsevier

    Professor Chun Hei Antonio Cheung

  11. Treat cancers by targeting survivin: Just a dream or future reality?

    Article • Cancer Treatment Reviews, November 2013, Elsevier

    Professor Chun Hei Antonio Cheung

  12. Survivin – biology and potential as a therapeutic target in oncology

    Article • OncoTargets and Therapy, October 2013, Taylor & Francis

    Professor Chun Hei Antonio Cheung, Yung-Chieh Chang

  13. ChemInform Abstract: Cancer Targeted Nanoparticles Specifically Induce Apoptosis in Cancer Cells and Spare Normal Cells

    Article • ChemInform, April 2012, Wiley

    Professor Chun Hei Antonio Cheung

  14. Targeting cathepsin S induces tumor cell autophagy via the EGFR–ERK signaling pathway

    Article • Cancer Letters, April 2012, Elsevier

    Professor Chun Hei Antonio Cheung

  15. Cancer Targeted Nanoparticles Specifically Induce Apoptosis in Cancer Cells and Spare Normal Cells

    Article • Australian Journal of Chemistry, January 2012, CSIRO Publishing

    Professor Chun Hei Antonio Cheung

  16. Enhancement of non-homologous end joining DNA repair capacity confers cancer cells resistance to the novel selenophene compound, D-501036

    Article • Cancer Letters, October 2011, Elsevier

    Professor Chun Hei Antonio Cheung

  17. BPR1K653, a Novel Aurora Kinase Inhibitor, Exhibits Potent Anti-Proliferative Activity in MDR1 (P-gp170)-Mediated Multidrug-Resistant Cancer Cells

    Article • PLoS ONE, August 2011, PLOS

    Professor Chun Hei Antonio Cheung

  18. Aurora kinase inhibitor patents and agents in clinical testing: an update (2009 – 10)

    Article • Expert Opinion on Therapeutic Patents, May 2011, Informa Healthcare

    Professor Chun Hei Antonio Cheung

  19. Investigations of survivin: the past, present and future

    Article • Frontiers in Bioscience, January 2011, Frontiers in Bioscience

    Professor Chun Hei Antonio Cheung

  20. Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer

    Article • Investigational New Drugs, November 2010, Springer Science + Business Media

    Professor Chun Hei Antonio Cheung

  21. Proliferative and protective effects of SurR9-C84A on differentiated neural cells

    Article • Journal of Neuroimmunology, October 2010, Elsevier

    Professor Chun Hei Antonio Cheung

  22. Cancer Cells Acquire Mitotic Drug Resistance Properties Through Beta I-Tubulin Mutations and Alterations in the Expression of Beta-Tubulin Isotypes

    Article • PLoS ONE, September 2010, PLOS

    Professor Chun Hei Antonio Cheung

  23. Chamaecypanone C, a novel skeleton microtubule inhibitor, with anticancer activity by trigger caspase 8-Fas/FasL dependent apoptotic pathway in human cancer cells

    Article • Biochemical Pharmacology, May 2010, Elsevier

    Professor Chun Hei Antonio Cheung

  24. Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells

    Article • Molecular Cancer, January 2010, Springer Science + Business Media

    Professor Chun Hei Antonio Cheung

  25. A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy

    Article • Cancer Cell International, January 2010, Springer Science + Business Media

    Professor Chun Hei Antonio Cheung

  26. Aurora kinase inhibitors in preclinical and clinical testing

    Article • Expert Opinion on Investigational Drugs, April 2009, Informa Healthcare

    Professor Chun Hei Antonio Cheung

  27. Advances in Aurora kinase inhibitor patents

    Article • Expert Opinion on Therapeutic Patents, March 2009, Informa Healthcare

    Professor Chun Hei Antonio Cheung

  28. Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers

    Article • Molecular Cancer, January 2009, Springer Science + Business Media

    Professor Chun Hei Antonio Cheung